Tag: dialysis

The Vascular Access Devices Market Companies Quadrant delivers a thorough analysis of the global vascular access devices sector. Highlighting prominent players, innovations, and trends, it identifies the top 25 companies as quadrant leaders among over 100 evaluated. Vascular access devices (VADs), crucial for treatments like chemotherapy and dialysis, are set to grow from USD 5.99 billion in 2024 to USD 9.05 billion by 2030 at a 7.1% CAGR, fueled by rising demand and investments despite a skilled professional shortage. Key players include Beckton Dickinson, Teleflex, and ICU Medical, known for expanding portfolios through strategic acquisitions and innovations. The quadrant evaluates companies based on revenue, growth strategies, and product footprint across device types and applications.

The Medical Filtration Companies Quadrant offers a detailed analysis of the global medical filtration market, spotlighting key players, technological advancements, and market trends. This report categorizes the top 15 companies, including leaders like Merck KGaA, 3M, and Danaher, each excelling in areas such as healthcare and life sciences. Medical filtration is crucial for removing contaminants from fluids, ensuring safety and purity in applications like dialysis and drug delivery. Techniques include microfiltration and ultrafiltration, driven by chronic disease prevalence and regulatory standards. This innovation-rich market is essential for patient safety and product integrity in healthcare.

DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic^® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation injury, and sepsis